Syndax Pharmaceuticals (NASDAQ: SNDX) has recently appointed Steven Closter as its Chief Commercial Officer, effective immediately. Closter brings over 30 years of commercial experience in the biopharmaceutical industry, having overseen more than a dozen product launches and indication expansions. Before joining Syndax, he served in various roles at Sunovion Pharmaceuticals and Sumitomo Pharma America, ultimately as Vice President, Brand Strategy and Launch Excellence. He was responsible for global pre-commercialization, launch, marketing, sales, and market access strategies for products across neurology, psychiatry, and primary care therapeutics.
Closter’s appointment comes at a pivotal moment for Syndax as the company is on track for two potential first* and best-in-class product launches in 2024. These include Revumenib, a highly selective inhibitor of the menin–kmt2a binding interaction, and Axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. These therapies are expected to be delivered to people living with cancer this year.
Syndax CEO Michael A. Metzger expressed confidence in Closter’s ability to lead the company’s commercial strategy and operations, including marketing, sales, and market access. Metzger also thanked Steve Sabus, who is departing for personal reasons, for his contributions to Syndax and for assisting in seamlessly transitioning the role to Steven Closter.
The company is looking forward to Closter's contributions as they work toward a successful transition to a fully integrated commercial business. Syndax Pharmaceuticals is dedicated to developing an innovative pipeline of cancer therapies and is poised for success in the anticipated launch of Revumenib and Axatilimab. As a result of these announcements, the company's shares have moved -5.5% on the market, and are now trading at a price of $22.23. For the full picture, make sure to review Syndax Pharmaceuticals's 8-K report.
